In the US, Epoprostenol (epoprostenol systemic) is a member of the drug class agents for pulmonary hypertension and is used to treat Pulmonary Arterial Hypertension.
US matches:
- Epoprostenol
- Epoprostenol Intravenous
- Epoprostenol Sodium
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
B01AC09
CAS registry number (Chemical Abstracts Service)
0035121-78-9
Chemical Formula
C20-H32-O5
Molecular Weight
352
Therapeutic Categories
Vasodilator
Antiplatelet agent, prostacyclin
Chemical Name
Prosta-5,13-dien-1-oic acid, 6,9-epoxy-11,15-dihydroxy-, (5Z,9α,11α,13E,15S)-
Foreign Names
- Epoprostenolum (Latin)
- Epoprostenol (German)
- Époprosténol (French)
- Epoprostenol (Spanish)
Generic Names
- Epoprostenol (OS: USAN)
- Époprosténol (OS: DCF)
- PGI₂ (IS)
- PGX (IS)
- Prostacyclin (IS)
- Prostaglandin I₂ (IS)
- Prostaglandin X (IS)
- U 53217 (IS)
- Epoprostenol Sodium (OS: BAN, USAN)
- U 53217 A (IS: Upjohn)
Brand Names
- Epoprostenol Sodium
Actelion, United States; Teva USA, United States
- Flolan
Glaxo SmithKline, Spain; GlaxoSmithKline, Australia; GlaxoSmithKline, Belgium; GlaxoSmithKline, Canada; GlaxoSmithKline, Switzerland; GlaxoSmithKline, Czech Republic; GlaxoSmithKline, Denmark; GlaxoSmithKline, Estonia; GlaxoSmithKline, France; GlaxoSmithKline, United Kingdom; GlaxoSmithKline, Ireland; GlaxoSmithKline, Israel; GlaxoSmithKline, Italy; GlaxoSmithKline, Japan; GlaxoSmithKline, Luxembourg; GlaxoSmithKline, Malta; GlaxoSmithKline, Netherlands; GlaxoSmithKline, Norway; GlaxoSmithKline, Singapore; GlaxoSmithKline, United States; IFET, Greece
International Drug Name Search
Glossary
BAN | British Approved Name |
DCF | Dénomination Commune Française |
IS | Inofficial Synonym |
OS | Official Synonym |
Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
USAN | United States Adopted Name |
Click for further information on drug naming conventions and
International Nonproprietary Names.